PTO/SR/21 (08-03)

	U.S. Patern	Approved for use through 07/31/2006. OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE
RADE!!	Application Number	n of information unless it displays a valid OMB control number. 10/665,793
TRANSMITTAL	Filing Date	September 19, 2003
FORM	First Named Inventor	Edward J. Kaplan
(to be used for all correspondence after initial filing)	Art Unit	1616
(to be asserted an correspondence area made many)	Examiner Name	M. Hartley
Total Number of Pages in This Submission	Attorney Docket Number	KAP 100 CIP
	10011750	
ENC	LOSURES (Check all that	After Allowance communication
Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s)	Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): 2 pages of PTO 1449; 15 references
under 37 CFR 1.52 or 1.53	TARRIANT ATTORNE	EV OD AGENT
	OF APPLICANT, ATTORNI	
Patrea L Pabst, Esq., Reg. No.		up LLP
Individual name 400 Colony Square, Suite 1200	o, Aliania, GA 30301	
Signature		
Date July		
CERTIFIC	CATE OF TRANSMISSION	I/MAILING
I hereby certify that this correspondence is being facs sufficient postage as first class mail in an envelope act the date shown below. Typed or printed name	imile transmitted to the USPTO or	deposited with the United States Postal Service with
Roma Berman	1 1	
Signature And C	1 Benen	Date July <u>29</u> , 2004
This collection of information by required by 37 CFR 1.5. The inprocess) an application. Confidentiality is governed by 35 U.S gathering, preparing, and submitting the completed application amount of time you require to complete this form and/or suggested.	S.C. 122 and 37 CFR 1.14. This collect on form to the USPTO, Time will vary de	epending upon the individual case. Any comments on the

amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE finformation unless it displays a valid OMR control number Paperwork Reduction Act of 1995, no persons are required to re

for EV 2004
for FY 2004

(\$) 0

Effective 10/01/2003. Patent fees are subject to annual revis

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

espond to a concentor or time	THICKOTT CHICOCH, CROPICITO C. TONIC CONT. C. T. C.			
Complete if Known				
Application Number	10/665,793			
Filing Date	September 19, 2003			
First Named Inventor	Edward J. Kaplan			
Examiner Name	M. Hartley			
Art Unit	1616			
Attorney Docket No.	KAP 100 CIP			

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)				
Check Credit card Money Other None	3. ADDITIONAL FEES				
Deposit Account:	Large Entity Small Entity				
Donosit	Fee Fee Fee Fee Description Code (\$) Fee	Paid			
Account Number	1051 130 2051 65 Surcharge - late filing fee or oath				
Deposit Account Pabst Patent Group LLP	1052 50 2052 25 Surcharge - late provisional filing fee or cover sheet				
Name	1053 130 1053 130 Non-English specification				
The Director is authorized to: (check all that apply) Charge fee(s) indicated below Credit any overpayments	1812 2,520 1812 2,520 For filing a request for ex parte reexamination				
Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) or any underpayment of fee(s)	1804 920* 1804 920* Requesting publication of SIR prior to Examiner action				
Charge fee(s) indicated below, except for the filing fee	1805 1,840* 1805 1,840* Requesting publication of SIR after				
to the above-identified deposit account.	Examiner action				
FEE CALCULATION	1251 110 2251 55 Extension for reply within first month 1252 420 2252 210 Extension for reply within second month				
1. BASIC FILING FEE	1252 420 2252 210 Extension for reply within second month 1253 950 2253 475 Extension for reply within third month				
Large Entity Small Entity Fee Fee Fee Fee Fee Fee Description Fee Paid	1254 1,480 2254 740 Extension for reply within fourth month				
Code (\$) Code (\$)	1255 2,010 2255 1,005 Extension for reply within fifth month				
1001 770 2001 385 Utility filing fee	1401 330 2401 165 Notice of Appeal				
1002 340 2002 170 Design filing fee	1401 330 2401 105 Notice of Appeal				
1003 530 2003 265 Plant filing fee	1403 290 2403 145 Request for oral hearing				
1004 770 2004 385 Reissue filing fee					
1005 160 2005 80 Provisional filing fee					
1 SUBTOTAL (1) (\$) 0					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1453 1,330 2453 665 Petition to revive - unintentional	$\neg \neg$			
Fee from	1301 1,330 2301 003 Builty issue fee (01 reissue)				
Total Claims 26 -26* = 0 X	1502 460 2503 320 Plant issue fee				
Independent 3 2** - 0 x	1460 130 1460 130 Petitions to the Commissioner				
Claims S - S - Co A - S - Co A - S - Co A -	1807 50 1807 50 Processing fee under 37 CFR 1.17(q)				
Large Entity Small Entity	1806 180 1806 180 Submission of Information Disclosure Stmt				
Fee Fee Fee Fee Description	Recording each natent assignment per				
Code (\$) Code (\$) 1202 18 2202 9 Claims in excess of 20	property (times number of properties)				
1201 86 2201 43 Independent claims in excess of 3	1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))				
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 2810 385 For each additional invention to be examined (37 CFR 1.129(b))				
1204 86 2204 43 ** Reissue independent claims over original patent	1801 770 2801 385 Request for Continued Examination (RCE)				
1205 18 2205 9 ** Reissue claims in excess of 20	1802 900 1802 900 Request for expedited examination of a design application				
and over original patent	Other fee (specify)				
SUBTOTAL (2) (\$) U Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0					
of number previously pare, if yespen, Not Neissaes, see above					
SUBMITTED BY	(Complete (if applicable))				
I	Registration No. 24 294 Telephone (404) 970 2454				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

31,284

Telephone (404) 879-2151

July 2

2004

Date

Pabst |

Patrea L

Name (Print/Type)

Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ed

Edward J. Kaplan

Serial No.:

10/665,793

Art Unit:

1616

Filed:

September 19, 2003

Examiner:

M. Hartley

For:

FLEXIBLE AND/OR ELASTIC BRACHYTHERAPY SEED OR STRAND

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including 2 pages of Form PTO-1449, and copies of the 15 documents cited therein.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S.S.N.: 10/665,793 Filed: September 19, 2003

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

U.S. Patents

Number	Issue Date	<u>Patentee</u>	Class/Subclass
4,379,138	04/05/1983	Pitt et al.	424/78
5,296,229	03/22/1994	Grandjean	424/444
5,916,998	06/29/1999	Ferrutti et al.	528/196
6,011,092	01/04/2000	Seppala et al.	524/47
6,228,969	05/08/2001	Lee et al.	528/80
6,290,982	09/18/2001	Seppala et al.	424/426

U.S. Patent Applications

<u>Number</u>	Issue Date	<u>Patentee</u>	Class/Subclass
2003/0132546	07/17/2003	Yamauchi et al.	264/241
2003/0139567	07/24/2003	Kim et al.	528/354

Foreign Documents

Number	Publication Date	<u>Patentee</u>	Country
WO 03/066705	08/14/2003	Polyganics B.V.	PCT

Publications

Ikeda et al. "Polyurethane elastomer with PEO-PTMO-PEO soft segment for sustainedrelease of drugs." *Biomaterials* 11(8): 553-560 (1990).

Lee et al. "Elastic biodegradable poly(glycolide-co-caprolactone) scaffold for tissue engineering." *Journal of biomedical materials research* 66A(1): 29-37 (2003).

Pitt et al. "Sustained drug delivery systems II: factors affecting release rates from poly(caprolactone) and related biodegradable polyesters." *Journal of pharmaceutical sciences* 68(12): 1534-1538 (1979).

Saad et al. "Development of degradable polyesterurethanes for medical applications: in vitro and in vivo evaluations." *Journal of biomedical materials research* 36(1): 65-74 (1997).

Seung et al. "Synthesis and characterization of elastic PLGA/PCL/PLGA tri-block copolymers." *J Biomater Sci Polymer Edn* 13(10): 1163-1173 (2002).

U.S.S.N.: 10/665,793 Filed: September 19, 2003

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Wada et al. "In vitro evaluation of sustained drug release from biodegradable elastomer." *Pharmaceutical Research* 8(10): 1292-1296 (1991).

U.S.S.N.: 10/665,793

Filed: September 19, 2003

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: July 24, 20

PABST PATENT GROUP LLP

400 Colony Square, Suite 1200

1201 Peachtree Street

Atlanta, Georgia 30361

(404) 879-2151 (Telephone)

(404) 879-2160 (Fax)

A (10-96	1
551-0031	+

Substitute for form 1449A/PTO	Corr	nplete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/665,793
AUG 3	Filing Date	September 19, 2003
ار الله الله الله الله الله الله الله ال	First Named Inventor	Edward J. Kaplan
Chr. C. W.	Group Art Unit	1616
VI a mark:		
TRANS.	Examiner Name	M. Hartley

U.S. PATENT DOCUMENTS							
xaminer Cite Initials* No.1		US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number Kind Code ² (if known)					
		4,379,138	Pitt et al.	04-05-1983			
		5,296,229	Grandjean	03-22-1994	· · · · · · · · · · · · · · · · · · ·		
		5,916,998	Ferrutti et al.	06-29-1999			
		6,011,092	Seppala et al.	01-04-2000			
		6,228,969	Lee et al.	05-08-2001			
		6,290,982	Seppala et al.	09-18-2001			
		2003/0132546	Yamauchi et al.	07-17-2003			
		2003/0139567	Kim et al.	07-24-2003			
			····				

					OREIGN PATENT DOCUMEN	ITS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Foreign Patent Document Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T®
		Office.3	Number ⁴	Kind Code ⁵ (if known)			:	
		PCT	WO 03/066705		Polyganics B.V.	08-14-2003		
		ļ						
		ļ		ļ				
	L		1	THER ART	NON PATENT LITERATURE	DOCUMENTS		
F					In In	ata Cansidarad		-

Examiner's	Date Considered	
Signature		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Under the P	aperwork Reduction Substitute fo			ection of information unless it contains a valid OMB control number Complete if Known		
PE	/	ATEME	TION DISCLOSURE NT BY APPLICANT ny sheets as necessary)	Application Number	10/665,793	
		•	•	Filing Date	September 19, 2003	
	DE! BOT			First Named Inventor	Edward J. Kaplan	
A TRA	De.			Group Art Unit	1616	
				Examiner Name	M. Hartley	
Sheet	2	of	2	Attorney Docket Number	KAP 100 CIP	

Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
		Ikeda et al. "Polyurethane elastomer with PEO-PTMO-PEO soft segment for sustainedrelease of drugs." Biomaterials 11(8): 553-560 (1990).			
		Lee et al. "Elastic biodegradable poly(glycolide-co-caprolactone) scaffold for tissue engineering." Journal of biomedical materials research 66A(1): 29-37 (2003).			
		Pitt et al. "Sustained drug delivery systems II: factors affecting release rates from poly(caprolactone) and related biodegradable polyesters." Journal of pharmaceutical sciences 68(12): 1534-1538 (1979).			
		Saad et al. "Development of degradable polyesterurethanes for medical applications: in vitro and in vivo evaluations." Journal of biomedical materials research 36(1): 65-74 (1997).			
		Seung et al. "Synthesis and characterization of elastic PLGA/PCL/PLGA tri-block copolymers." <i>J Biomater Sci Polymer Edn</i> 13(10): 1163-1173 (2002).			
		Wada et al. "In vitro evaluation of sustained drug release from biodegradable elastomer." <i>Pharmaceutical Research</i> 8(10): 1292-1296 (1991).			
		·			

Examiner's	Date C	Considered	
Signature			

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.